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Introduction: Percutaneous transvenous mitral commissurotomy (PTMC) is one of the nonsurgical
commissurotomy in patients with hemodynamically signiﬁcant mitral stenosis. The aim of the present study is
to assess the immediate, intermediate and long term outcomes of PTMC in relation to initial mitral valve score
and to assess its impact on mitral valve area (MVA), clinical and hemodynamic parameters.
Methods: It is a retrospective study on a total of 303 patientswho underwent successful PTMC between 1994 and
2001, were called back and their preprocedural, immediate post and follow-up (4, 7 and 10 year.) data were
analyzed. Echo was performed in patients before and after PTMC. The patients were divided into two groups,
group-I with Wilkins score of ≤8 and group-II with Wilkins score between 8 and 12.
Results: PTMC patients who have completed 4, 7 and 10 years of follow up revealed the mitral valve area, mean
transmitral gradient and pulmonary artery pressures to be signiﬁcantly different in both group-I and group-II. At
all follow-up periods group-II showed higher restenosis than group-I, but its distribution between the groups
was not statistically signiﬁcant (χ2= 0.029; p=0.986). Furthermore, losses of theMVAduring different periods
of follow-up revealed a gradual increase in attrition.
Conclusions:MV score, Mitral valve area, mitral gradient and pulmonary artery pressures appeared to inﬂuence
the outcome of PTMC. A clear-cut prospective assessment of individual components of themitral valve apparatus
using 3-D echocardiographic images may provide a more precise prediction of the PTMC outcome based on its
morphological abnormalities.© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Percutaneous transvenousmitral commissurotomy (PTMC) is one of
the nonsurgical commissurotomy in patients with hemodynamically
signiﬁcant mitral stenosis [1]. The important steps in performing
PTMC are atrial septal puncture and crossing the mitral valve [2,3].
This procedure is cost effective, less invasive and free from complica-
tions related to surgery and very rarely leads to pericardial tamponade
[4,5]. The assessment of the mitral valve morphology is very important
because the success of PTMC is grater in patients with thin, pliable valve
leaﬂets and little subvalvular disease [6,7]. Although PTMC procedure
increases the mitral valve area (MVA), in some patients this procedure
is unable to obtain an optimal MVA, indicating the need for clinical
evaluation before selecting the patient for the procedure [8–10].
Furthermore, other PTMC related complications such as cardiac
perforation, embolic stroke and mitral regurgitation limit the procedure.l College & Research Institute,
thi Sriram).
land Ltd. This is an open access articlSometimes,mitral regurgitation andmitral restenosiswarrant emergency
mitral valve replacement or a redo of PTMC [11,12].
TheWilkins score is one of the most widely used echocardiographic
scoring systems that is used to assess the suitability of themitral valve's
morphology for PTMC [13,14]. The Wilkins score assigns approximate
measurements to assess mitral leaﬂets thickening, mobility, calciﬁca-
tion, and the degree of the subvalvular apparatus disease. Several imme-
diate, short and long term follow-up studies revealed that patients with
a score of less than or equal to 8 showed better outcome than thosewith
a score of more than 8 of Wilkins score [15]. The present study is aimed
to assess the immediate, short and long term outcomes of PTMC in
patients with severe mitral stenosis at Department of Cardiology, Sri
Ramachandra Medical College & Research Institute, Chennai, India.
2. Materials and methods
2.1. Subjects
This retrospective observational study was carried out on 303
patients of mitral stenosis who underwent successful PTMC betweene under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Variations in echocardiography variables at pre-PTMC between group-I and group-II.
Group-I
(Wilkins score ≤ 8)
Group-II
(Wilkins score N 8)
P value
NYHA: Class-I & Class-II 86 (28.4) 37 (12.2)
NYHA: Class-III 90 (29.7) 90 (29.7) b0.001
MVA 0.99 ± 0.13 0.98 ± 0.13 0.452
MG 12.45 ± 3.47 14.12 ± 3.27 b0.001
PAP 55.98 ± 14.5 65.97 ± 12.43 b0.001
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Institute, Chennai. Patients of either sex, aged between 7 and 58 years
having symptomatic mitral stenosis with mitral valve area b1.5 cm2
were included in the study. Patients suffering frommild mitral stenosis
(MVA N 1.5 cm2) with grade II mitral regurgitation (≥2/4), left atrial
thrombus, congestive heart failure (NYHA class IV), Wilkins
score N 12, patients who needed open heart surgery or other valves or
coronary artery diseases/ascending aortas were excluded from the
study. Principles outlined in the Declaration of Helsinki were strictly
followed during data collection.
2.2. Pre-procedural evaluation
Patients were subjected to an initial evaluation where physical
examination and detailed functional disability were assessed by New
York Heart Association classiﬁcation; chest X-ray and surface electro-
cardiogram were recorded in all patients. A complete echo Doppler
study was performed in all patients 24 to 48 h before PTMC. All
hemodynamic measurements were recorded.
2.3. Procedure
The self-positioning single balloon (Inoue balloon) was used for
the commissurotomy in all patients. The upper limit of the balloon
dilating diameter was chosen according to the patient's body weight
(26mm/b50 kg, 28 mm/50–60 kg, and 30mm/N60 kg). PTMCwas per-
formed with all aseptic precautions through femoral vein approach.
Inﬂation was started at 1–2 mm less than the maximum diameter. If
the hemodynamic resultswere suboptimal, the procedurewas repeated
by increasing the balloon diameter to the predetermined level. If opti-
mal hemodynamic results were not obtained at the balloon's maximum
diameter, additional inﬂationwas not attempted as a general rule. Once
the balloon catheter's tip traversed the interatrial septum, the stiffening
cannula for the central lumen was used to facilitate the passage of
the balloon portion into the left atrium. Once in the left atrium the
balloon was maneuvered into the left ventricle. The balloon was then
inﬂated with diluted contrast material until the waist of the balloon
disappeared.
2.4. Post-procedural evaluation
Immediately after completing the procedure, all hemodynamic
measurements were repeated. To evaluate the severity of the resultant
mitral regurgitation, if any, cine left ventriculography in the right
anterior oblique view was performed in all patients. The severity of
mitral regurgitation was graded by the Seller's classiﬁcation from 0 to
4+. A complete echo Doppler study was repeated again 24 h after the
procedure by both transthoracic and multiplane transesophageal
echocardiography using HP sonos 2500 imaging. Valve morphology
was assessed using Wilkins score. Mitral regurgitation was quantiﬁed
and left atrial clots were excluded. 2D views of the mitral valve were
obtained from parasternal windows and planimetery was performed.
Continuous wave Doppler recordings through the mitral valve were
obtained from the apical four chamber window and mitral valve area
was estimated by using pressure half time principle. Three cardiac
cycles were recorded and their results were averaged for every patient.
The peak and mean transmitral gradient and pulmonary artery
pressures were also measured. Follow up was viewed at 4, 7 and 10
years. For analysis patients who underwent the procedure in 1994,
1995, and 1996 were grouped into the 10 year segment, 1997, 1998,
and 1999 into the 7 year segment. Both immediately after PTMC and
at follow up themitral Valve Area (MVA), mean gradient (MG), pulmo-
nary artery pressure (PAP) and functional class of the patients were
recorded. The patients were divided into two prominent groups
depending on their mitral valve score. Group-I consisted of patientswith mitral valve score of ≤8 and group-II with mitral valve score
between 8 and 12.2.5. Statistical analysis
The data were analyzed using the SPSS software (version 11.0,
Chicago, IL). Categorical variables were summarized as number
(percent), and continuous variables as either median (range) or
mean ± standard deviation. Comparisons of immediate-PTMC versus
follow-up measures were performed using the paired t test.3. Results
Our study included 303 patients who returned for follow up after
successful PTMC. About three-fourth of patients (72%) were 21–
40 years old followed by 13.2% 41–50 years and 11.6% were below 20
years. Only 3.2% were N50 years old. The mean age of the patients was
32.05 ± 9 years. A female predominance was observed in the series
with female to male ratio of 3:1. The duration of follow-up was 4, 7
and 10 years respectively for 27.4%, 19.8% and 52.8% of patients. Out of
303 patients, 184 (60.7%) showed a Wilkins score of less than or equal
to 8 and 119 (39.3%) showed more than 8. About 59.4% of the patients
were categorized as NYHA functional class-III, 38% as class-II and 2.6%
as class-IV. Variations in the echocardiographic variables at pre-PTMC
between group-I and group-II were presented in Table 1. The distribu-
tion of NYHA functional classes was signiﬁcantly different between
group-I and group-II patients (p b 0.001). Mitral valve area was not
signiﬁcantly different between group-I and group-II patients (p =
0.452). Both group-I and group-II patients showed signiﬁcant differ-
ences in pulmonary artery pressure (p b 0.001) and mean transmitral
pressure gradients (p b 0.001). Mitral valve area signiﬁcantly increased
following PTMC in both group-I (p b .001) and II (p b 0.001) patients.
Both pulmonary artery pressure and mean transmittal pressure
gradients were signiﬁcantly reduced following PTMC (Table 2).
Comparison ofmeanMVA values of immediate post-PTMC and different
follow-up periods showed signiﬁcant reduction inMVA over a period of
time and the trend was similar in both group-I and group-II (Table 3).
Both pulmonary artery pressure (PAP) and mean gradient (MG) were
signiﬁcantly increased during follow-up in group-I and group-II
(Table 3). Distribution of these echocardiographic variables revealed
that the MVA, MG and PAP were signiﬁcantly different in different
follow-up periodswhen compared to baseline (Table 4). The percentage
of restenosis during different periods of follow-up in both group-I and
group-IIwasdepicted in Fig. 1. At all follow-upperiods group-II resteno-
sis was higher compared to group-I, but its distribution between the
groups was not statistically signiﬁcant (χ2 = 0.029; p = 0.986). Losses
of the MVA during different periods of follow-up revealed a gradual
increase in the attrition (Fig. 2). The NHYA functional class category
distribution between group-I and group-II was not statistically
signiﬁcant for 4 and 7 years of follow-up. However, classes III and IV
showed signiﬁcant functional impairment (OR = 4.61; p b 0.001)
compared to classes I and II after 10 years of follow-up (Table 5).
Table 2
Variations in the echocardiography variables at pre-PTMC and post-PTMC in Group-I and
Group-II.
Pre-PTMC Post-PTMC P value
MVA Group-I 0.99 ± 0.13 2.08 ± 0.27 b0.001
Group-II 0.98 ± 0.13 2.0 ± 0.0 b0.001
MG Group-I 12.45 ± 3.47 6.41 ± 2.62 b0.001
Group-II 14.12 ± 3.27 8.74 ± 2.83 b0.001
PAP Group-I 55.98 ± 14.48 35.66 ± 12.49 b0.001
Group-II 65.97 ± 12.43 48.07 ± 11.72 b0.001
Table 4
Distribution of MVA, MG and PAP at different follow-up periods in comparison with
baseline.
Duration N Variable (Mean ± SD) P value
MVA
Baseline 303 0.99 ± 0.13 –
Immediate 303 2.05 ± 0.21 b0.001
4 years 83 1.75 ± 0.46 b0.001
7 years 60 1.78 ± 1.18 b0.001
10 years 160 1.64 ± 0.49 b0.001
MG
Baseline 303 13.11 ± 3.48 –
Immediate 303 7.32 ± 2.93 b0.001
4 years 83 9.17 ± 4.11 b0.001
7 years 60 10.37 ± 5.18 b0.001
10 years 160 9.62 ± 4.59 b0.001
PAP
Baseline 303 59.9 ± 14.64 –
Immediate 303 40.46 ± 13.68 b0.001
4 years 83 45.57 ± 14.24 b0.001
7 years 60 50.4 ± 23.26 b0.001
10 years 160 48.2 ± 21.23 b0.001
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Analysis of 303 successful PTMC patients who have completed 4, 7
and 10 years of follow up revealed the mitral valve area, mean
transmitral gradient and pulmonary artery pressures to be signiﬁcantly
different in both groups I and II. At all follow-up periods group-II
showed higher restenosis than group-I. Furthermore, losses of the
MVA during different periods of follow-up revealed a gradual increase
in the attrition.
The higher MVA gain in group-I than in group-II indicated the
intervention to be effective in patients with Wilkins score of less than
8. These ﬁndings were consistent with a previous study that showed a
signiﬁcant favorable impact on immediate post PTMC in patients with
b8 Wilkins score [16]. Several others also found mitral anatomy to be
the best predictor of mitral opening though a good result could also be
obtained in cases with a high score as well [17].
Rheumatic process and/or abnormal turbulences are generated
by the already deformed valve. Both mechanisms might contribute
to further commissural fusion, thickening, and calciﬁcation of valvu-
lar and subvalvular structures both in natural and previously
commissurotomized valves. In this study series we found that the
meanMVA loss progressively increasedwith time in both the groups.
Previous studies demonstrated the rapid progression of valve dis-
ease in those subjects with a greater mitral valve echocardiographic
score and higher peak and mean transmitral gradients [18]. Long-
term clinical and echocardiographic follow-up after PTMC in Spanish
patients revealed a mild mitral valve area loss (0.13 ± 0.21 cm2) and
it gradually increased with time. Follow-up of 7 years revealed a
MVA decrease of 0.2 cm2 irrespective of score, which is in fact small-
er than that reported in untreated valves [19]. In contrast to this,
Spanish study group's ﬁndings showed an accelerated MVA loss in
valves with a higher score [20].
Restenosis is an ambiguous term that includes a mixture of poor
result, inaccuracies in MVA determination, true restenosis, and disease
progression. Its deﬁnition could be made on a clinical basis or in termsTable 3
Comparison of mitral valve area, mean gradient and PAP during different follow-up
periods.
Parameters Group I (Mean ± SD) Group II (Mean ± SD) P value
Mitral valve area
Immediate 2.10 ± 0.322 1.850 ± 0.271 b0.001
4 years 1.821 ± 0.379 1.603 ± 0.265 b0.001
7 years 1.627 ± 0.423 1.476 ± 0.388 b0.001
10 years 1.715 ± 0.528 1.354 ± 0.478 b0.001
Mean gradient
Immediate 5.88 ± 2.17 7.93 ± 2.77 b0.001
4 years 7.89 ± 3.81 9.24 ± 3.89 b0.05
7 years 9.19 ± 3.77 9.93 ± 1.13 b0.001
10 years 8.01 ± 4.16 11.45 ± 4.32 b0.001
PAP
Immediate 36.16 ± 12.59 47.45 ± 13.23 b0.001
4 years 39.70 ± 11.03 52.79 ± 15.47 b0.001
7 years 42.07 ± 14.28 50.62 ± 23.62 b0.001
10 years 40.41 ± 20.92 60.69 ± 20.63 b0.001of mitral area, absolute area loss, % of area loss, or loss of gain. With all
these confounding factors, it is not surprising that restenosis rate after
PTMC has ranged from 3% to 70% at 1 to 3 years [21]. When restenosis
is deﬁned as a 50% loss of area gain, patients with a poor initial result
meet restenosis criteria with only a mild area loss. This fact explains
the apparent contradictory ﬁnding that patients with a high score had
a smaller mitral area loss but a higher restenosis rate than those with
a lower score. The percentage of restenosis is different at different
follow-up periods in different studies. In Spanish patients, the restenosis
ratewas 10% at 4 years, 18% at 5 years and 39% at the end of 7 years [19].
In American patients restenosis rate was 40% at the end of 6 years [22].
Though the percentages for restenosis in groups A and Bwere divergent
across different follow-up periods we could establish that a low pre-
procedure Wilkins score resulted in lesser restenosis rates only in the
10 year segment. Post-PTMC Cox regression analysis however identiﬁed
mitral echocardiographic score of N8 as a predictor of restenosis [23].
The mean mitral diastolic gradient in our series reduced signiﬁcantly
in both the groups. A similar trend in mean transmitral gradient fall
was reported in two independent studies [24,25]. We could establish
no statistically signiﬁcant difference in mean transmitral reduction
between group-I and group-II either immediately after the procedure
or at different follow-up periods. From this it is evident that though the
diastolic gradient dropped signiﬁcantly after PTMC in both the groups
it gradually increased, and also worsened with time. Extrapolation to
establish a connection between MVA and symptomatic worsening
however would require further study.
The immediate results obtained with the pulmonary artery systolic
pressures were not dissimilar from the transmitral mean with a dropFig. 1. Restenosis of mitral valve during different periods of follow-up.
Fig. 2. Loss of the mitral valve area during different periods of follow-up.
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who reported a reduction in PA pressures from 51.2 ± 14.8 to 33.9 ±
8.8 mm Hg. In contrast to the mean mitral gradient the reduction in
PA pressurewas signiﬁcantly lower in group-I as in group-II immediate-
ly after PTMC. Also,whilewe found an insigniﬁcant difference in pulmo-
nary artery pressure increase at 4, and 7 years follow up, the pulmonary
pressures were signiﬁcantly higher in group-II patients at the end of 10
years. Although numerous studies have implicated higher post-PTMC
pulmonary artery pressure as independent predictor of combined
events at long-term follow-up, clear cut distinction with respect to
valve score is yet to be deﬁned [10].
Clinical improvement assessed by the NYHA functional class
revealed the absence of statistically signiﬁcant difference in the
achieved clinical improvement between the groups immediately after
PTMC. A signiﬁcant difference in functional impairment was only
established at 10 years of follow-up, between groups-I and IIwith a less-
er number of group-I patients exhibiting impairment. In patients with
signiﬁcant MVA loss, the functional impairment is consistent with
increased attrition and time. In a multivariate analysis, a high NYHA in
pre-PTMC class as an independent predictor of poor functional results
as well as combined events at long term follow up was noticed [27,28].
The study done by Mahfouz et al. showed signiﬁcant correlation
between the posteriormitral valve leaﬂet to anterior mitral valve leaﬂet
length ratio (PMVL/AMVL length ratio) and post- balloon mitral
valvuloplasty mitral valve area and the cardiac events [29]. Unfortu-
nately, PMVL/AMVL length ratio was not analyzed in our study. The
present study suffers from a number of the following limitations. Firstly,
data were collected from only one clinical setting, thus generalizability
of these ﬁndings might be limited. Secondly, the convenient sampling
strategy adopted in this study limits the extrapolation of results to all
PTMC procedures. Lastly, this particular study underutilised the poten-
tial of the posterior mitral valve leaﬂet to anterior mitral valve leaﬂet
length ratio (PMVL/AMVL length ratio). However, in summary, MV
score, Mitral valve area, mitral gradient and pulmonary pressures with
isolated symptomatic worsening needs further insight and larger stud-
ies not only to improve event free survival but also to improve the
symptom free survival. A clear-cut prospective assessment of individual
components of the mitral valve apparatus using 3-D echocardiographic
images may provide more precise prediction of the PTMC outcome
based on its morphological abnormalities.Table 5
Change in the NYHA functional class after 10 years of follow-up.
NYHA Group-I Group-II OR (95% CI) P value
Classes I & II 74 (24.4) 27 (8.9) Reference
Classes III & IV 22 (7.3) 37 (12.2) 4.61 (2.32–9.17) b0.001Conﬂict of interest
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